Ultrasonography of the Neuromuscular Degeneration Behavior in Amyotrophic Lateral Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03683875|
Recruitment Status : Completed
First Posted : September 25, 2018
Last Update Posted : November 5, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurological disease.
An exhaustive and frequent clinical evaluation can lead to establish an adequate and early treatment of the consequences of its evolution.
- To evaluate the evolution of diaphragmatic and peripheral neuromuscular degeneration by ultrasound examination in patients with ALS and to establish possible evolution patterns.
- To verify the relationship between the degenerative peripheral and diaphragmatic neuromuscular changes evaluated by ultrasonography and changes in clinical scales frequently used.
- To compare the ultrasonographic features of subjects with ALS and a sample of healthy subjects Methods. A longitudinal observational study in a consecutive sample of patients diagnosed with ALS will be realized. All the patients will be examined 3 times, with an interval of at least 3 months between tests. Bilateral and cross sectional ultrasonography of several peripheral muscles and diaphragm will be performed at rest and during muscle contraction. All the images will be processed and analyzed for obtaining morphometric variables (muscle thickness) and textural ones (echogenic variation, entropy, homogeneity, textural contrast and correlation). Frequency of twitches will be also recorded in peripheral muscles.Also clinical features will be noted, every time of the 3 exams, from Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-r), British Medical Council Research Scale(MRC), and routine pulmonary tests.
|Condition or disease|
|Amyotrophic Lateral Sclerosis|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||26 participants|
|Target Follow-Up Duration:||9 Months|
|Official Title:||Ultrasonography of the Neuromuscular Degeneration Behavior in ALS: a Longitudinal Study|
|Actual Study Start Date :||October 1, 2018|
|Actual Primary Completion Date :||October 1, 2018|
|Actual Study Completion Date :||March 10, 2020|
- Measuring thickness of peripheral muscles using an ultrasound device [ Time Frame: 3 months ]These measurements will be carried out in the biceps brachialis, forearm flexors, thenar eminence muscle, quadriceps and tibialis anterior which will be compared between patient with ALS and control group.
- Measuring echointensity of peripheral muscles using an ultrasound device [ Time Frame: 3 months ]These measurements will be carried out in the biceps brachialis, forearm flexors, thenar eminence muscle, quadriceps and tibialis anterior which will be compared between patient with ALS and control group.
- Measuring sonoelastography of peripheral muscles using an ultrasound device [ Time Frame: 3 months ]These measurements will be carried out in the biceps brachialis, forearm flexors, thenar eminence muscle, quadriceps and tibialis anterior which will be compared between patient with ALS and control group.
- Thickness Fraction of the Diaphragm in ALS patients and control group. [ Time Frame: 3 months ]It is calculated as the difference between thickness at end inspiration and end expiration
- Diaphragmatic Excursion (quiet and forced) of the Diaphragm in ALS patients and control group [ Time Frame: 3 months ]Displacement of the right diaphragm dome
- Measurement of muscle fasciculations using an ultrasound device [ Time Frame: 3 months ]Each peripheral muscle will be screened during 30 seconds
- Measurement of muscle strength using Medical Research Council Scale (MRCs) [ Time Frame: 3 months ]
Graded on the medical research council scale. This scale grades muscle power on a scale of 0 to 5:
Grade 0: no movement is observed Grade 1: only a trace or flicker of movement is seen or flet in the muscle. or fasciculation is observed Grade 2: movement is possible only if the resistance of gravity is removed Grade 3: movement against gravity is possible but not against resistance of the examiner Grade 4: muscle stregth is reduced but muscle contraction can move joint against gravity and resistance Grade 5: muscle contracts normally against full resistance
- Measurement Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-r) [ Time Frame: 3 months ]
Questionnaire with 12 items with a score from 0 to 4 each item:
- Handwriting 5a. Cutting food and handling utensils (patients without gastrostomy) 5b. Cutting food and handling utensils(scale for patients with gastrostomy)
6. Dressing and hygiene 7. Turning in bed and adjusting bed clothes 8. Walking 9. Climbing stairs 10. Dyspnea 11. Orthopnea 12. Respiratory insufficiency
There are three main pathways of progression, the questions are also divided in relation to the types of onset. Questions 1 to 3 are related to bulbar onset, questions 4 to 9 are related to limb onset and questions 10-12 are related to respiratory onset. The Scale goes from 0 to 48, more points meaning better situation.
- Measuring Forced Vital Capacity [ Time Frame: 3 months ]This volume expressed in liters will be measured in supine and seated positions.
- Maximal Inspiratory Pressure (MIP) [ Time Frame: 3 months ]Measure of the strength of inspiratory muscles expressed in centimeters of water, is the highest mouth pressure sustained for 1 s during a maximum inspiratory effort
- Sniff- nasal inspiratory pressure (SNIP) [ Time Frame: 3 months ]It consists of measuring nasal pressure in an occluded nostril during a maximal sniff performed through the contralateral nostril, expressed in centimeters of water
- Peak Cough Flow (PCF) [ Time Frame: 3 months ]Maximal peak cough flow expressed in liters per minute
- Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) [ Time Frame: 3 months ]Obtained by a radial arterial blood sample and expressed in millimeters of mercury
- Cumulative time percentage with SpO2 under 90% (CT90) [ Time Frame: 3 months ]SpO2 is an estimate of arterial oxygen saturation expressed in percentage under 90% obtained from a nocturnal oximetry
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- Definite ALS
- Primary Lateral Sclerosis (PLS)
- Other forms of motor neuron disorders
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03683875
|Hospital General Universitario Santa Lucia|
|Cartagena, Murcia, Spain, 30202|
|Principal Investigator:||Antonio Tomás Ríos Cortés||HOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA - SERVICIO MURCIANO DE SALUD|
|Responsible Party:||Antonio Tomás Ríos-Cortés, Msc Physiotherapist, Hospital General Universitario Santa Lucia|
|Other Study ID Numbers:||
|First Posted:||September 25, 2018 Key Record Dates|
|Last Update Posted:||November 5, 2021|
|Last Verified:||October 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases